Desley van Zoggel

Chapter 7 136 References 1. van Zoggel DMGI, Bosman SJ, Kusters M, et al. Preliminary results of a cohort study of induction chemotherapy-based treatment for locally recurrent rectal cancer. Br J Surg. 2018;105:447–452. 2. Voogt ELK, vanZoggel DMGI, KustersM, et al. ImprovedOutcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer. Ann Surg Oncol. 2020;8–11. 3. Peacock O, Chang GJ. “Watch and Wait” for complete clinical response after neoadjuvant chemoradiotherapy for rectal cancer. Minerva Chirurgica. 2019;74:481–495. 4. Dossa F, ChesneyTR, Acuna SA, et al. Awatch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic reviewand meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501–513. 5. KustersM, BosmanS, vanZoggelD, et al. Local Recurrence in theLateral LymphNodeCompartment: ImprovedOutcomes with Induction Chemotherapy CombinedwithMultimodality Treatment. Ann Surg Oncol. 2016;23:1883–1889. 6. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. 7. SchellingM, Avril N, Nährig J, et al. Positron EmissionTomographyUsing [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer. J Clin Oncol. 2000;18:1689–1695. 8. Wieder H, Brücher B, Zimmerman F, et al. Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment. J Clin Oncol. 2004;22:900–908. 9. Bokemeyer C, Kollmannsberger C, Oechsle K, et al. Early prediction of treatment response to highdose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET. Br J Cancer. 2002;86:506–511. 10. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. Journal of NuclearMedicine.;50 . Epub ahead of print May 1, 2009. DOI: 10.2967/jnumed.108.057307. 11. Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200. 12. RullierE, Rouanet P, TuechJJ, et al. Organpreservation for rectal cancer (GRECCAR2): aprospective, randomised, open-label, multicentre, phase 3 trial. Lancet (London, England). 2017;390:469–479. 13. PelvEx Collaborative. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). BJS open.;5 . Epub ahead of print May 7, 2021. DOI: 10.1093/BJSOPEN/ZRAB029. 14. Mandard A -M, Dalibard F, Mandard J -C, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680–2686. 15. Jang JK, Choi SH, Park SH, et al. MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: a systematic review and meta-analysis for accuracy. Eur Radiol. 2020;30:2312–2323. 16. Votrubova J, BelohlavekO, JaruskovaM, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2006;33:779–784.